Alec Stranahan's Stock Ratings

B of A Securities Analyst

Alec Stranahan is an analyst at B of A Securities. Analyst ratings are quantitative and qualitative analysis of a stock by Wall Street stock rating analysts. Stock ratings consist of expected future growth, current stock valuation and macroeconomic trends. Updated 09/06/2024

Overall Average Return

-18.5%

Smart Score

42.3%

Overall Average Return Percentile

13th

Number of Ratings

24
Data brought to you by Benzinga APIs

Recent Analyst Stock Rating News

Meta To Rally Around 35%? Here Are 10 Top Analyst Forecasts For Thursday
Tesla To $250? Here Are 10 Other Price Target Changes For Thursday
Morgan Stanley cut Tesla, Inc. (NASDAQ: TSLA) price target from $330 to $250. Morgan Stanley analyst Adam Jonas maintained an Overweight rating on the stock. Tesla shares rose 4.4% to $117.65 in pre-market trading.
Here's What To Watch On Novavax Stock As Latest COVID-19 Vaccine Gains Approval
Novavax, Inc (NASDAQ: NVAX) gapped up 10% to start the trading day on Wednesday, but at press time, the stock had given back almost all of its gains to trade mostly flat.
Why This Novavax Analyst Remains Bearish After COVID Vaccine Panel Vote
A Bank of America analyst remains bearish on Novavax, Inc (NASDAQ: NVAX) after a regulatory panel approved Novavax’s Emergency Use Authorization request fo
5 Small-Cap S&P Stocks To Buy With The Most Upside
The S&P 500 is one of the most popular U.S. stock indices and is often what investors and experts are referring to when they mention the "stock market." However, there's more to the market than large-cap stocks.
Why Novavax Shares Are Diving Today
Novavax, Inc. (NASDAQ: NVAX) shares are trading lower by 14.20% at $50.14. Bank of America's Alec Stranahan initiated coverage of Novavax with an Underperform rating and a price target of $35.
Novavax Has Limited Pipeline Upside, Says BofA Analyst: What's Next?
Although Novavax, Inc’s (NASDAQ: NVAX) shares have tanked 59% year to date, there is still room for a further decline, according to BofA Securities. The Novavax Analyst: Alec Stranahan initiated coverage of Novavax with an Underperform rating and a price target of $35.
7 High-Risk Stocks For Market Gamblers
Casinos are just starting to open back up following COVID-19 shutdowns, but it may still be a while before some gamblers are willing to venture back to Vegas or even their local casino. Sports gamblers are still waiting for the return of Major League Baseball and other pro and college sports leagues.
Analyst Trims NextCure Price Target Following SITC Presentation, Still Sees Big Upside
The Best Trading Research Platform
For Retail Investors and Professional Trades Alike.
Get Started for Free